TEV-48574

DRUG4 trials

Sponsors

Teva Branded Pharmaceutical Products R&D Inc., Teva Branded Pharmaceutical Products R&D LLC, Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

AsthmaColitis, UlcerativeCrohn DiseaseCrohn’s diseaseUlcerative colitis

Phase 2

A Study to Test if TEV-48574 is Effective in Relieving Asthma

TerminatedNCT04545385

Teva Branded Pharmaceutical Products R&D, Inc.Asthma

Start: 2020-10-07End: 2022-01-17Updated: 2023-03-13

A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

CompletedNCT05499130

Teva Branded Pharmaceutical Products R&D, Inc.Colitis, Ulcerative, Crohn Disease

Start: 2022-09-30End: 2024-11-12Updated: 2026-03-27

A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative Colitis or Crohn’s Disease (RELIEVE UCCD)

CompletedCTIS2024-511089-36-00

Teva Branded Pharmaceutical Products R&D Inc.Crohn’s disease, Ulcerative colitis

Start: 2023-03-17End: 2024-11-12Target: 214Updated: 2024-12-09

A Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult Patients with Moderate to Severe Ulcerative Colitis or Crohn’s Disease who completed the treatment phase of the Dose-Ranging Study (RELIEVE UCCD LTE)

Active, not recruitingCTIS2024-515027-11-00

Teva Branded Pharmaceutical Products R&D LLCCrohn’s disease, Ulcerative colitis

Start: 2023-06-29Target: 184Updated: 2025-12-05

Related Papers

Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.

2026-07-16

Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.

2026-07-16

OP41 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active ulcerative colitis: Results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging, basket trial (RELIEVE UCCD)

Journal of Crohn s and Colitis2025-01-016 citations

OP40 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active Crohn’s disease: results from a phase 2b, randomised, double-blind, placebo-controlled dose-ranging, basket trial (RELIEVE UCCD)

Journal of Crohn s and Colitis2025-01-014 citations

P998 Phase 2 basket design study evaluating the efficacy and safety of an anti-TL1A antibody (TEV-48574) in moderate to severe ulcerative colitis or Crohn's Disease (RELIEVE UCCD)

Journal of Crohn s and Colitis2024-01-0110 citations

P1061 TEV-48574, an anti-TL1A antibody in development for use in IBD, is safe and well tolerated following 16 weeks of subcutaneous treatment in adults with severe uncontrolled T2-low/non T2 asthma

Journal of Crohn s and Colitis2024-01-015 citations